ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-23 06:37:10,2025-10-23T06:37:10-04:00,2025-10-23,Eli Lilly allows Cipla to sell weight loss drug under new brand in India,"Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a separate brand in the country, the companies said on Thursday.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-allows-cipla-sell-weight-loss-drug-under-new-brand-india-2025-10-23/,https://images.financialmodelingprep.com/news/eli-lilly-allows-cipla-to-sell-weight-loss-drug-20251023.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-23 08:00:48,2025-10-23T08:00:48-04:00,2025-10-23,Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats,"Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S. manufacturing investments position it well for regulatory and political developments. Despite sector headwinds and cautious market sentiment, LLY's robust earnings momentum and positive analyst revisions support continued outperformance.",seekingalpha.com,https://seekingalpha.com/article/4832340-eli-lilly-stock-accelerates-on-obesity-data-while-novo-nordisk-retreats,https://images.financialmodelingprep.com/news/eli-lilly-accelerates-on-obesity-data-while-novo-nordisk-20251023.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-23 11:06:19,2025-10-23T11:06:19-04:00,2025-10-23,Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?,Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2775305/eli-lilly-lly-earnings-expected-to-grow-should-you-buy?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2775305,https://images.financialmodelingprep.com/news/eli-lilly-lly-earnings-expected-to-grow-should-you-20251023.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-23 11:40:13,2025-10-23T11:40:13-04:00,2025-10-23,"Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?",Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.,zacks.com,https://www.zacks.com/stock/news/2775453/lilly-up-10-in-a-month-should-you-buy-sell-or-hold-the-stock?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2775453,https://images.financialmodelingprep.com/news/lilly-up-10-in-a-month-should-you-buy-20251023.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 05:15:00,2025-10-24T05:15:00-04:00,2025-10-24,2 Things Investors Should Know About Eli Lilly's $5 Billion Investment to Improve Its Drug Production Capacity,Eli Lilly's new U.S. facility will be just the first of four that it plans to build in the country. The company expects to eventually make 100% of drugs for American patients in the U.S.,fool.com,https://www.fool.com/investing/2025/10/24/2-things-investors-should-know-about-eli-lillys-5/,https://images.financialmodelingprep.com/news/2-things-investors-should-know-about-eli-lillys-5-20251024.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 06:45:00,2025-10-24T06:45:00-04:00,2025-10-24,Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis,"New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared to approved monthly maintenance dosing  Lilly submitted these data to the FDA for a potential label update for EBGLYSS  If approved, EBGLYSS would be a first-line biologic that offers the option of monotherapy with once every eight-week maintenance dosing in moderate-to-severe atopic dermatitis uncontrolled by topicals  INDIANAPOLIS , Oct. 24, 2025 /PRNewswire/ -- New results show Eli Lilly and Company's (NYSE: LLY) EBGLYSS (lebrikizumab-lbkz) sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks (Q8W) compared with once every four weeks (Q4W), supporting a potential additional, less frequent maintenance dosing option for more individualized treatment of patients with moderate-to-severe atopic dermatitis. These findings from the Phase 3 ADjoin extension trial will be presented at the 2025 Fall Clinical Dermatology Conference, taking place Oct. 23-26 in Las Vegas.1 ""For people managing the persistent symptoms of eczema, hesitancy about frequent injections can add to the already heavy toll of this disease,"" said Peter Lio, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-ebglyss-lebrikizumab-lbkz-delivered-durable-disease-control-when-administered-once-every-eight-weeks-in-patients-with-moderate-to-severe-atopic-dermatitis-302593427.html,https://images.financialmodelingprep.com/news/lillys-ebglyss-lebrikizumablbkz-delivered-durable-disease-control-when-administered-20251024.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 06:45:00,2025-10-24T06:45:00-04:00,2025-10-24,Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial,"This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials  New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) INDIANAPOLIS , Oct. 24, 2025 /PRNewswire/ -- New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to 1 month to",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-baricitinib-delivered-near-complete-scalp-hair-regrowth-at-one-year-for-adolescents-with-severe-alopecia-areata-in-phase-3-brave-aa-peds-trial-302593426.html,https://images.financialmodelingprep.com/news/lillys-baricitinib-delivered-nearcomplete-scalp-hair-regrowth-at-one-year-20251024.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 06:46:42,2025-10-24T06:46:42-04:00,2025-10-24,"Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion",Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for alopecia and eczema.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-reports-promising-data-alopecia-eczema-drugs-eyes-label-expansion-2025-10-24/,https://images.financialmodelingprep.com/news/eli-lilly-reports-promising-data-for-alopecia-and-eczema-20251024.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 08:23:00,2025-10-24T08:23:00-04:00,2025-10-24,Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears,"Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.",benzinga.com,https://www.benzinga.com/markets/equities/25/10/48401923/mounjaro-maker-eli-lilly-jumps-in-quality-despite-trump-fueled-price-cut-fears,https://images.financialmodelingprep.com/news/mounjaro-maker-eli-lilly-jumps-in-quality-despite-trumpfueled-price-20251024.jpeg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 08:30:00,2025-10-24T08:30:00-04:00,2025-10-24,Lilly to Acquire Adverum Biotechnologies,"Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif. , Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc. (""Adverum""), including its lead product candidate, Ixo-vec.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-to-acquire-adverum-biotechnologies-302593482.html,https://images.financialmodelingprep.com/news/lilly-to-acquire-adverum-biotechnologies-20251024.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 10:11:43,2025-10-24T10:11:43-04:00,2025-10-24,Eli Lilly to buy gene therapy developer Adverum in about $262 million deal,"Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 million, aiming to strengthen its pipeline with an experimental eye disease treatment.",reuters.com,https://www.reuters.com/legal/transactional/eli-lilly-buy-gene-therapy-developer-adverum-about-262-million-deal-2025-10-24/,https://images.financialmodelingprep.com/news/eli-lilly-to-buy-gene-therapy-developer-adverum-in-20251024.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-24 10:31:40,2025-10-24T10:31:40-04:00,2025-10-24,Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings,"LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.",zacks.com,https://www.zacks.com/stock/news/2776275/here-s-how-eli-lilly-s-oncology-drugs-are-poised-ahead-of-q3-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2776275,https://images.financialmodelingprep.com/news/heres-how-eli-lillys-oncology-drugs-are-poised-ahead-20251024.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-25 11:41:00,2025-10-25T11:41:00-04:00,2025-10-25,"Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM","NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Adverum will receive $3.56 per share in cash plus one non-transferable contingent value right (CVR) entitling the holder to receive up to an additional $8.",businesswire.com,https://www.businesswire.com/news/home/20251025519753/en/Adverum-Biotechnologies-Investor-Alert-By-The-Former-Attorney-General-Of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Adverum-Biotechnologies-Inc.---ADVM/,https://images.financialmodelingprep.com/news/adverum-biotechnologies-investor-alert-by-the-former-attorney-general-20251025.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-26 02:40:50,2025-10-26T02:40:50-04:00,2025-10-26,Pharmaceutical Stocks To Watch Now – October 24th,"Eli Lilly and Company, Wellgistics Health, Pfizer, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies engaged in the research, development, manufacturing, and sale of prescription drugs, biologics, and vaccines. For investors, these stocks are typically driven by factors like",defenseworld.net,https://www.defenseworld.net/2025/10/26/pharmaceutical-stocks-to-watch-now-october-24th.html,https://images.financialmodelingprep.com/news/pharmaceutical-stocks-to-watch-now-october-24th-20251026.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-26 07:01:35,2025-10-26T07:01:35-04:00,2025-10-26,Wall Street Week Ahead,Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.,seekingalpha.com,https://seekingalpha.com/article/4833469-wall-street-week-ahead,https://images.financialmodelingprep.com/news/wall-street-week-ahead-20251026.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-26 08:15:00,2025-10-26T08:15:00-04:00,2025-10-26,Eli Lilly: Is Another Monster Quarter Coming,"October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stock price has risen by 13.1%. On October 24th, Eli Lilly surprised me by announcing its acquisition of Adverum Biotechnologies, a developer of gene therapies for the treatment of ocular diseases, for up to $261.7 million.",seekingalpha.com,https://seekingalpha.com/article/4833427-eli-lilly-is-another-monster-quarter-coming,https://images.financialmodelingprep.com/news/eli-lilly-is-another-monster-quarter-coming-20251026.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 06:45:00,2025-10-27T06:45:00-04:00,2025-10-27,Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis,"Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its burden on patients By Week 12, patients experienced a 55% reduction in daily episodes of bowel urgency from baseline, with severity reduced by more than half by Week 28 At Week 28, nearly one-third of patients were able to delay using the restroom for at least 15 minutes after feeling urgency, up from 4% at baseline INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis (UC) and bowel urgency experienced early improvements in bowel urgency severity, frequency and stool deferral time by Week 12. These outcomes continued to improve through 28 weeks.",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-omvoh-mirikizumab-mrkz-demonstrated-early-and-sustained-improvement-in-bowel-urgency-outcomes-for-patients-with-ulcerative-colitis-302594395.html,https://images.financialmodelingprep.com/news/lillys-omvoh-mirikizumabmrkz-demonstrated-early-and-sustained-improvement-in-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 07:31:00,2025-10-27T07:31:00-04:00,2025-10-27,Should You Buy Eli Lilly Stock Before Oct. 30?,"Wall Street expects good news when Lilly announces its Q3 results on Oct. 30. Lilly's stock might not perform as you think it will, even if it beats analysts' estimates.",fool.com,https://www.fool.com/investing/2025/10/27/should-you-buy-eli-lilly-stock-before-october-30th/,https://images.financialmodelingprep.com/news/should-you-buy-eli-lilly-stock-before-oct-30-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 09:25:03,2025-10-27T09:25:03-04:00,2025-10-27,"LLY Stock To $1,100?","Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca signed drug pricing agreements with the Trump Administration to cut prescription drug prices and boost domestic manufacturing investments.",forbes.com,https://www.forbes.com/sites/greatspeculations/2025/10/27/lly-stock-to-1100/,https://images.financialmodelingprep.com/news/lly-stock-to-1100-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 10:17:00,2025-10-27T10:17:00-04:00,2025-10-27,Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics,"Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",zacks.com,https://www.zacks.com/stock/news/2777661/seeking-clues-to-lilly-lly-q3-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2777661,https://images.financialmodelingprep.com/news/seeking-clues-to-lilly-lly-q3-earnings-a-peek-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 10:56:17,2025-10-27T10:56:17-04:00,2025-10-27,"Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings",Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.,zacks.com,https://www.zacks.com/stock/news/2777853/buy-sell-or-hold-lilly-stock-key-tips-ahead-of-q3-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2777853,https://images.financialmodelingprep.com/news/buy-sell-or-hold-lilly-stock-key-tips-ahead-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 11:00:00,2025-10-27T11:00:00-04:00,2025-10-27,"Down 15%, Should You Buy the Dip on Eli Lilly?",Eli Lilly is one of the largest drug companies in the world. The pharmaceutical giant's stock price is 15% below its 2024 high-water mark.,fool.com,https://www.fool.com/investing/2025/10/27/down-15-should-you-buy-the-dip-on-eli-lilly/,https://images.financialmodelingprep.com/news/down-15-should-you-buy-the-dip-on-eli-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 12:06:06,2025-10-27T12:06:06-04:00,2025-10-27,What's in Store for These 5 Pharma Bigwigs This Earnings Season?,"As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",zacks.com,https://www.zacks.com/stock/news/2777998/what-s-in-store-for-these-5-pharma-bigwigs-this-earnings-season?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview_esp-2777998,https://images.financialmodelingprep.com/news/whats-in-store-for-these-5-pharma-bigwigs-this-earnings-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 12:36:04,2025-10-27T12:36:04-04:00,2025-10-27,"BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares","BDF-GESTION sold 4,149 shares of Eli Lilly and Company; Transaction value was $3.1 million Transaction represents 0.37% of BDF-GESTION's 13F reportable assets under management Post-trade stake: 19,949 shares valued at $15.22 million as of September 30, 2025 Position now represents 1.8% of fund AUM, which places it outside the fund's top five holdings",fool.com,https://www.fool.com/coverage/filings/2025/10/27/bdf-gestion-dumps-4100-lly-shares-worth-31-million/,https://images.financialmodelingprep.com/news/bdfgestion-trims-its-eli-lilly-lly-stake-by-4149-20251027.png
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 13:27:00,2025-10-27T13:27:00-04:00,2025-10-27,Baron Health Care Fund Q3 2025 Top Contributors And Detractors,"Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.",seekingalpha.com,https://seekingalpha.com/article/4833710-baron-health-care-fund-q3-2025-top-contributors-and-detractors,https://images.financialmodelingprep.com/news/baron-health-care-fund-q3-2025-top-contributors-and-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 14:00:00,2025-10-27T14:00:00-04:00,2025-10-27,Lilly declares fourth-quarter 2025 dividend,"INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-declares-fourth-quarter-2025-dividend-302595631.html,https://images.financialmodelingprep.com/news/lilly-declares-fourthquarter-2025-dividend-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-27 16:05:00,2025-10-27T16:05:00-04:00,2025-10-27,Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis,"Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen  Omvoh single-injection dosing will be available for U.S. patients in early 2026 This is the third FDA approval for Omvoh this year, following approvals for Crohn's disease and a citrate-free formulation INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC). ""In clinical practice, we see that simplifying maintenance treatment can make a difference in the overall patient experience,"" said Miguel Regueiro, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-omvoh-mirikizumab-mrkz-approved-by-us-fda-as-a-single-injection-maintenance-regimen-in-adults-with-ulcerative-colitis-302595733.html,https://images.financialmodelingprep.com/news/lillys-omvoh-mirikizumabmrkz-approved-by-us-fda-as-a-singleinjection-20251027.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-28 10:30:44,2025-10-28T10:30:44-04:00,2025-10-28,Is It Worth Investing in Lilly (LLY) Based on Wall Street's Bullish Views?,"When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?",zacks.com,https://www.zacks.com/stock/news/2778887/is-it-worth-investing-in-lilly-lly-based-on-wall-street-s-bullish-views?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|average_broker_rating-2778887,https://images.financialmodelingprep.com/news/is-it-worth-investing-in-lilly-lly-based-on-20251028.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-28 10:40:55,2025-10-28T10:40:55-04:00,2025-10-28,"Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings","Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.",cnbc.com,https://www.cnbc.com/2025/10/28/healthy-returns-eli-lilly-merck-gilead-and-abbvie-earnings-preview.html,https://images.financialmodelingprep.com/news/healthy-returns-what-to-expect-from-eli-lilly-merck-20251028.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-28 14:30:00,2025-10-28T14:30:00-04:00,2025-10-28,"Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients","New AI capabilities will help scientists identify, optimize and validate new molecules Additional applications include manufacturing, medical imaging and enterprise AI agents INDIANAPOLIS , Oct. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA. The supercomputer will power an ""AI factory,"" a specialized computing infrastructure that manages the entire AI lifecycle from data ingestion and training to fine-tuning and high-volume inference.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-partners-with-nvidia-to-build-the-industrys-most-powerful-ai-supercomputer-supercharging-medicine-discovery-and-delivery-for-patients-302597285.html,https://images.financialmodelingprep.com/news/lilly-partners-with-nvidia-to-build-the-industrys-most-20251028.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-28 14:30:00,2025-10-28T14:30:00-04:00,2025-10-28,Eli Lilly Partners With Nvidia to Build AI Supercomputer for Drug Discovery,The drugmaker hopes an Nvidia-chip powered supercomputer will help it find new drugs and accelerate lengthy R&D timelines.,wsj.com,https://www.wsj.com/tech/ai/eli-lilly-partners-with-nvidia-to-build-ai-supercomputer-for-drug-discovery-e37247b3,https://images.financialmodelingprep.com/news/eli-lilly-partners-with-nvidia-to-build-ai-supercomputer-20251028.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-28 14:30:59,2025-10-28T14:30:59-04:00,2025-10-28,"Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development","Eli Lilly and Nvidia are partnering to build what the companies call the pharmaceutical industry's ""most powerful"" supercomputer and so-called AI factory to help accelerate drug discovery and development across the broader sector. It's the latest stride by Nvidia and the pharmaceutical industry to harness AI to try to shorten the time it takes to bring cures to patients, while reducing costs at every stage of the drug discovery and development process.",cnbc.com,https://www.cnbc.com/2025/10/28/eli-lilly-nvidia-supercomputer-ai-factory-drug-discovery.html,https://images.financialmodelingprep.com/news/eli-lilly-nvidia-partner-to-build-supercomputer-ai-factory-20251028.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-28 14:31:46,2025-10-28T14:31:46-04:00,2025-10-28,Lilly partners with Nvidia on AI supercomputer to speed up drug development,"Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten development cycles, getting medicines to people faster.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-partners-with-nvidia-ai-supercomputer-speed-up-drug-development-2025-10-28/,https://images.financialmodelingprep.com/news/lilly-partners-with-nvidia-on-ai-supercomputer-to-speed-20251028.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-28 20:10:00,2025-10-28T20:10:00-04:00,2025-10-28,1 Undervalued Growth Stock Down 8% to Buy Before 2026,Eli Lilly's performance over the past year hasn't been as strong as usual. The company's growth prospects justify its higher-than-average valuation.,fool.com,https://www.fool.com/investing/2025/10/28/1-undervalued-growth-stock-down-8-buy-before-2026/,https://images.financialmodelingprep.com/news/1-undervalued-growth-stock-down-8-to-buy-before-20251028.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 07:00:00,2025-10-29T07:00:00-04:00,2025-10-29,LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound,"Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials Strategic collaboration marks the first time patients using LillyDirect, Lilly's direct-to-consumer healthcare platform, can access self-pay pricing for Zepbound vials at a retail pharmacy location LillyDirect pick-up option at Walmart offers millions of Americans living with obesity additional convenience, access and choice in how they get their medication INDIANAPOLIS , Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Walmart Inc. (NYSE: WMT) today announced a collaboration to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect. Zepbound (ZEHP-bownd) vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November.",prnewswire.com,https://www.prnewswire.com/news-releases/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-up-option-with-direct-to-consumer-pricing-for-zepbound-302597663.html,https://images.financialmodelingprep.com/news/lillydirect-and-walmart-pharmacy-launch-first-retail-pickup-option-20251029.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 07:11:36,2025-10-29T07:11:36-04:00,2025-10-29,Lilly and Walmart launch first retail pick-up option for weight-loss drug,"Eli Lilly and Walmart said on Wednesday they are partnering to expand access to single-dose vials of Lilly's weight-loss drug Zepbound, which will be offered for pick-up at Walmart pharmacies nationwide by mid-November.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-walmart-launch-first-retail-pick-up-option-weight-loss-drug-2025-10-29/,https://images.financialmodelingprep.com/news/lilly-and-walmart-launch-first-retail-pickup-option-for-20251029.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 09:25:22,2025-10-29T09:25:22-04:00,2025-10-29,What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?,LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.,zacks.com,https://www.zacks.com/stock/news/2779881/what-s-the-driving-force-behind-eli-lilly-s-recent-acquisition-spree?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2779881,https://images.financialmodelingprep.com/news/whats-the-driving-force-behind-eli-lillys-recent-acquisition-20251029.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 10:06:33,2025-10-29T10:06:33-04:00,2025-10-29,"In Lilly vs Novo obesity drug battle, Trump price talks grab focus","As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are looking elsewhere: high-stakes price talks with U.S. President Donald Trump.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-vs-novo-obesity-drug-battle-trump-price-talks-grab-focus-2025-10-29/,https://images.financialmodelingprep.com/news/in-lilly-vs-novo-obesity-drug-battle-trump-price-20251029.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 10:30:00,2025-10-29T10:30:00-04:00,2025-10-29,Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States,"Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs INDIANAPOLIS , Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. This new investment will integrate advanced technologies and expand production capacity within the existing campus to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-announces-more-than-1-2-billion-investment-in-puerto-rico-facility-to-boost-oral-medicine-manufacturing-capacity-in-the-united-states-302597678.html,https://images.financialmodelingprep.com/news/lilly-announces-more-than-12-billion-investment-in-puerto-20251029.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 10:33:43,2025-10-29T10:33:43-04:00,2025-10-29,Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push,"Eli Lilly said on Wednesday it will invest more than $1.2 billion to expand its manufacturing site in Puerto Rico, as the drugmaker looks to increase its U.S. production capacity to hedge against potential tariffs.",reuters.com,https://www.reuters.com/sustainability/boards-policy-regulation/eli-lilly-invest-12-billion-puerto-rico-part-us-manufacturing-push-2025-10-29/,https://images.financialmodelingprep.com/news/eli-lilly-to-invest-12-billion-in-puerto-rico-20251029.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 14:19:31,2025-10-29T14:19:31-04:00,2025-10-29,"Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound","Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consumer prices through retail locations for the first time.  Starting in mid-November, cash-paying patients with a prescription can purchase single-dose vials of Zepbound at discounts of 50% or more through the retailer's nearly 4,600 pharmacy locations or via home delivery.",cnbc.com,https://www.cnbc.com/2025/10/29/eli-lilly-walmart-to-offer-discounted-retail-option-for-zepbound.html,https://images.financialmodelingprep.com/news/eli-lilly-walmart-to-offer-first-retail-pickup-option-for-20251029.jpeg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-29 16:45:00,2025-10-29T16:45:00-04:00,2025-10-29,Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal,"The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug.",barrons.com,https://www.barrons.com/articles/eli-lilly-earnings-stock-price-99b5da9b,https://images.financialmodelingprep.com/news/eli-lilly-reports-earnings-thursday-as-investors-await-trump-drug-20251029.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 02:09:33,2025-10-30T02:09:33-04:00,2025-10-30,Top Medical Stocks To Research – October 28th,"UnitedHealth Group, Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. ""Medical stocks"" are publicly traded companies whose primary business is healthcare - including pharmaceuticals, biotechnology, medical-device manufacturers, hospitals and clinics, diagnostics, and related suppliers and service providers.",defenseworld.net,https://www.defenseworld.net/2025/10/30/top-medical-stocks-to-research-october-28th.html,https://images.financialmodelingprep.com/news/top-medical-stocks-to-research-october-28th-20251030.png
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 02:09:35,2025-10-30T02:09:35-04:00,2025-10-30,Pharmaceutical Stocks To Keep An Eye On – October 28th,"Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies whose primary business is researching, developing, manufacturing, and marketing prescription drugs and related therapies. For investors, these stocks",defenseworld.net,https://www.defenseworld.net/2025/10/30/pharmaceutical-stocks-to-keep-an-eye-on-october-28th.html,https://images.financialmodelingprep.com/news/pharmaceutical-stocks-to-keep-an-eye-on-october-28th-20251030.jpeg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 06:45:00,2025-10-30T06:45:00-04:00,2025-10-30,"Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance",Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis.,prnewswire.com,https://www.prnewswire.com/news-releases/lilly-reports-third-quarter-2025-financial-results-highlights-rd-pipeline-momentum-and-raises-2025-guidance-302599148.html,https://images.financialmodelingprep.com/news/lilly-reports-thirdquarter-2025-financial-results-highlights-rd-pipeline-momentum-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 08:09:00,2025-10-30T08:09:00-04:00,2025-10-30,Eli Lilly's stock jumps as Zepbound sales nearly triple at lower prices,"Eli Lilly's stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.",marketwatch.com,https://www.marketwatch.com/story/eli-lillys-stock-jumps-as-zepbound-sales-nearly-triple-at-lower-prices-1c084836,https://images.financialmodelingprep.com/news/eli-lillys-stock-jumps-as-zepbound-sales-nearly-triple-at-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 08:50:46,2025-10-30T08:50:46-04:00,2025-10-30,5 Things to Know Before the Stock Market Opens,"Stock futures are losing ground amid a barrage of earnings reports from major companies, as investors assess the latest developments in trade talks and Federal Reserve Chair Jerome Powell's warning that more rate cuts aren't a certainty; President Donald Trump said his meeting with Chinese leader Xi Jinping resulted in a rare earths mineral agreement and a reduction in certain tariffs on China; shares of Meta (META) and Microsoft (MSFT) are losing ground after the Magnificent Seven members reported results late yesterday, while Alphabet (GOOG) shares are surging after the Google parent reported more than $100 billion in quarterly sales; Apple (AAPL) and Amazon (AMZN) are due to release their quarterly reports after the closing bell; and Eli Lilly (LLY) shares are rising after the company reported strong sales of weight loss drug Zepbound and diabetes treatment Mounjaro. Here's what you need to know today.",investopedia.com,https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-october-30-2025-11840105,https://images.financialmodelingprep.com/news/5-things-to-know-before-the-stock-market-opens-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 08:55:30,2025-10-30T08:55:30-04:00,2025-10-30,Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates,"Eli Lilly (LLY) came out with quarterly earnings of $7.02 per share, beating the Zacks Consensus Estimate of $6.02 per share. This compares to earnings of $1.18 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2781079/eli-lilly-lly-q3-earnings-and-revenues-surpass-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2781079,https://images.financialmodelingprep.com/news/eli-lilly-lly-q3-earnings-and-revenues-surpass-estimates-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 09:05:12,2025-10-30T09:05:12-04:00,2025-10-30,20% Upside For Eli Lilly Stock?,"Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli Lilly recently announced a significant partnership with Walmart to sell its popular weight-loss drug, Zepbound, at a discounted retail price through Walmart pharmacies.",forbes.com,https://www.forbes.com/sites/greatspeculations/2025/10/30/20-upside-for-eli-lilly-stock/,https://images.financialmodelingprep.com/news/20-upside-for-eli-lilly-stock-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 09:12:09,2025-10-30T09:12:09-04:00,2025-10-30,"Eli Lilly shares jump as blowout earnings, obesity drug demand fuel profit upgrade","Shares of Eli Lilly rose nearly 4% in premarket trading on Thursday after the pharmaceutical company reported third-quarter earnings that exceeded expectations and lifted its annual profit forecast. The company posted adjusted earnings of $7.02 per share for the quarter, well ahead of analysts' consensus estimate of $5.89.",invezz.com,https://invezz.com/news/2025/10/30/eli-lilly-shares-jump-as-blowout-earnings-obesity-drug-demand-fuel-profit-upgrade/,https://images.financialmodelingprep.com/news/eli-lilly-shares-jump-as-blowout-earnings-obesity-drug-demand-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 09:25:52,2025-10-30T09:25:52-04:00,2025-10-30,Eli Lilly Blows Away Q3 Earnings Expectations,"Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance.",247wallst.com,https://247wallst.com/investing/2025/10/30/eli-lilly-blows-away-q3-earnings-expectations/,https://images.financialmodelingprep.com/news/eli-lilly-blows-away-q3-earnings-expectations-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 09:58:28,2025-10-30T09:58:28-04:00,2025-10-30,"Eli Lilly Q3 earnings and revenue top estimates, boosted by weight loss drug demand","Eli Lilly and Co (NYSE:LLY) on Thursday reported third quarter 2025 financial results that handily beat Wall Street forecasts, as the company continued to see strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro.  The pharmaceutical giant's revenue for the quarter rose 54% year over year to $17.60 billion, surpassing the analyst consensus estimate of $16.01 billion, according to data provided by LSEG.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1081457,https://images.financialmodelingprep.com/news/eli-lilly-q3-earnings-and-revenue-top-estimates-boosted-by-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 10:05:19,2025-10-30T10:05:19-04:00,2025-10-30,"Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast","Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.",benzinga.com,https://www.benzinga.com/markets/earnings/25/10/48529099/mounjaro-and-zepbound-power-eli-lillys-54-revenue-jump-in-q3-hikes-2025-forecast,https://images.financialmodelingprep.com/news/mounjaro-and-zepbound-power-eli-lillys-54-revenue-jump-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 10:13:57,2025-10-30T10:13:57-04:00,2025-10-30,Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro,"Eli Lilly chairman and CEO David Ricks joins CNBC's “Squawk on the Street” team to discuss its quarterly earnings report that beat estimates, weight loss drug demand, its drug pipeline and more.",youtube.com,https://www.youtube.com/watch?v=Av51Q4RehYU,https://images.financialmodelingprep.com/news/eli-lilly-ceo-seeing-global-demand-for-weight-loss-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 11:25:42,2025-10-30T11:25:42-04:00,2025-10-30,Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs,"Strong sales of Eli Lilly's weight-loss treatments Mounjaro and Zepbound helped power strong quarterly earnings, and the drugmaker boosted its outlook.",investopedia.com,https://www.investopedia.com/eli-lilly-boosts-its-outlook-on-high-demand-for-popular-weight-loss-drugs-11840143,https://images.financialmodelingprep.com/news/eli-lilly-boosts-its-outlook-on-high-demand-for-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 11:30:18,2025-10-30T11:30:18-04:00,2025-10-30,"Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics","The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",zacks.com,https://www.zacks.com/stock/news/2781673/compared-to-estimates-lilly-lly-q3-earnings-a-look-at-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2781673,https://images.financialmodelingprep.com/news/compared-to-estimates-lilly-lly-q3-earnings-a-look-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 14:01:16,2025-10-30T14:01:16-04:00,2025-10-30,"Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales","Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year sales and earnings outlook.",zacks.com,https://www.zacks.com/stock/news/2781842/lilly-beats-on-q3-earnings-ups-view-mounjaro-zepbound-drive-sales?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2781842,https://images.financialmodelingprep.com/news/lilly-beats-on-q3-earnings-ups-view-mounjaro-zepbound-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 14:46:25,2025-10-30T14:46:25-04:00,2025-10-30,Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript,"Eli Lilly and Company ( LLY ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Mike Czapar - Director of Investor Relations David Ricks - Chairman, CEO & President Lucas Montarce - Executive VP & CFO Daniel Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology Patrik Jonsson - Executive VP & President of Lilly International Ilya Yuffa - Executive VP and President of Lilly USA & Global Customer Capabilities Anne White - Executive VP & President of Lilly Neuroscience Kenneth Custer - Executive VP & President of Lilly Cardiometabolic Health Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division James Shin - Deutsche Bank AG, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Steve Scala - TD Cowen, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.",seekingalpha.com,https://seekingalpha.com/article/4835587-eli-lilly-and-company-lly-q3-2025-earnings-call-transcript,https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-q3-2025-earnings-call-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 16:58:14,2025-10-30T16:58:14-04:00,2025-10-30,Eli Lilly: The Price Upside Just Increased,"Eli Lilly delivered robust Q3 2025 results and guidance for non-GAAP EPS for the second consecutive quarter. When I last checked on the stock, there was still 20% upside to LLY for the remainder of 2025. With higher guidance, this upside has risen too. Risks persist for the stock in terms of the policy environment, though. Its expected agreement with the US government is still pending, which could affect earnings.",seekingalpha.com,https://seekingalpha.com/article/4835836-eli-lilly-the-price-upside-just-increased,https://images.financialmodelingprep.com/news/eli-lilly-the-price-upside-just-increased-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-30 18:00:00,2025-10-30T18:00:00-04:00,2025-10-30,Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss,"Lilly's quarterly results Thursday, combined with Novo Nordisk's unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma's hottest.",wsj.com,https://www.wsj.com/health/pharma/the-day-pharmas-weight-loss-gold-rush-intensified-c5c32c11,https://images.financialmodelingprep.com/news/two-developments-thursdayeli-lillys-strong-quarterly-performance-and-novo-20251030.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-31 10:11:15,2025-10-31T10:11:15-04:00,2025-10-31,Eli Lilly's obesity and diabetes treatments fuel growth and spark bidding war,"The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.",fastcompany.com,https://www.fastcompany.com/91432558/eli-lilly-mounjaro-zepbound-obesity-diabetes,https://images.financialmodelingprep.com/news/eli-lillys-obesity-and-diabetes-treatments-fuel-growth-and-20251031.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-31 10:52:20,2025-10-31T10:52:20-04:00,2025-10-31,Eli Lilly Has A Solid Upside Now After Its Q3 Earnings,"Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. LLY posted a 54% YoY revenue jump and a 19% EPS beat, with management raising both sales and EPS guidance for the year. A strengthened drug pipeline, particularly for orforglipron's Phase III success, de-risks future earnings and promises sustained growth beyond 2027.",seekingalpha.com,https://seekingalpha.com/article/4836307-eli-lilly-has-a-solid-upside-now-after-its-q3-earnings,https://images.financialmodelingprep.com/news/eli-lilly-has-a-solid-upside-now-after-its-20251031.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-10-31 14:46:11,2025-10-31T14:46:11-04:00,2025-10-31,"Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say","Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.",benzinga.com,https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48571020/eli-lilly-seen-in-pole-position-for-growth-analysts-say,https://images.financialmodelingprep.com/news/eli-lilly-seen-in-pole-position-for-growth-analysts-20251031.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-01 05:47:08,2025-11-01T05:47:08-04:00,2025-11-01,Medical Stocks To Watch Now – October 30th,"Eli Lilly and Company, UnitedHealth Group, and Pfizer are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies that develop, manufacture, or deliver medical products and services - including pharmaceutical and biotech firms, medical device makers, diagnostic companies, hospitals, and healthcare insurers. Investors",defenseworld.net,https://www.defenseworld.net/2025/11/01/medical-stocks-to-watch-now-october-30th.html,https://images.financialmodelingprep.com/news/medical-stocks-to-watch-now-october-30th-20251101.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-01 08:00:23,2025-11-01T08:00:23-04:00,2025-11-01,"S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points","Three S&P 500 components, including JPMorgan Chase and Eli Lilly, are among five stocks near buy points.",investors.com,https://www.investors.com/news/sp-500-jpmorgan-eli-lilly-stocks-buy-points/,https://images.financialmodelingprep.com/news/sp-500-giants-jpmorgan-eli-lilly-lead-five-stocks-20251101.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-01 23:00:50,2025-11-01T23:00:50-04:00,2025-11-01,Top 15 High-Growth Dividend Stocks For November 2025,"The Top 15 High-Growth Dividend Stock list for November 2025 offers a 1.39% yield and 19.88% five-year dividend growth. Despite underperforming SPY and VIG in October, the watchlist targets a long-term 12% annual return and remains a strong starting point for research. Stocks are selected using Quality and Value tilts, aiming for higher yields, growth, and undervaluation, with an average 31% discount to fair value.",seekingalpha.com,https://seekingalpha.com/article/4836707-top-15-high-growth-dividend-stocks-for-november-2025,https://images.financialmodelingprep.com/news/top-15-highgrowth-dividend-stocks-for-november-2025-20251101.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-02 01:35:55,2025-11-02T01:35:55-04:00,2025-11-02,Top Medical Stocks To Keep An Eye On – October 31st,"Eli Lilly and Company, Pfizer, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies whose primary business is healthcare - including pharmaceutical and biotech firms, medical device and diagnostic manufacturers, and healthcare service providers like hospitals and insurers. Investors",defenseworld.net,https://www.defenseworld.net/2025/11/02/top-medical-stocks-to-keep-an-eye-on-october-31st.html,https://images.financialmodelingprep.com/news/top-medical-stocks-to-keep-an-eye-on-october-31st-20251102.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-02 08:00:01,2025-11-02T08:00:01-05:00,2025-11-02,Where the blockbuster weight loss drug market stands today — and what's coming next,"The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their medicines and bringing the next wave of obesity drugs to patients.",cnbc.com,https://www.cnbc.com/2025/11/02/whats-next-for-the-weight-loss-drug-market-pills-rivals-insurance.html,https://images.financialmodelingprep.com/news/where-the-blockbuster-weight-loss-drug-market-stands-today-20251102.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-03 08:30:00,2025-11-03T08:30:00-05:00,2025-11-03,Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide,"Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain INDIANAPOLIS , Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-plans-to-build-a-new-3-billion-facility-to-boost-oral-medicine-manufacturing-capacity-in-europe-for-patients-worldwide-302600462.html,https://images.financialmodelingprep.com/news/lilly-plans-to-build-a-new-3-billion-facility-20251103.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-03 08:32:48,2025-11-03T08:32:48-05:00,2025-11-03,Lilly to build $3 billion Dutch plant to boost weight-loss pill production,"Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other oral medicines.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-build-3-billion-dutch-plant-boost-weight-loss-pill-production-2025-11-03/,https://images.financialmodelingprep.com/news/lilly-to-build-3-billion-dutch-plant-to-boost-20251103.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 03:05:01,2025-11-04T03:05:01-05:00,2025-11-04,Top Pharmaceutical Stocks To Follow Now – November 2nd,"Eli Lilly and Company, Pfizer, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and commercialize prescription drugs, vaccines, and related therapies. For investors, they offer exposure to significant R&D and regulatory risk-stock performance is heavily",defenseworld.net,https://www.defenseworld.net/2025/11/04/top-pharmaceutical-stocks-to-follow-now-november-2nd.html,https://images.financialmodelingprep.com/news/top-pharmaceutical-stocks-to-follow-now-november-2nd-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 03:05:04,2025-11-04T03:05:04-05:00,2025-11-04,Best Medical Stocks To Watch Today – November 2nd,"Eli Lilly and Company, Pfizer, UnitedHealth Group, AbbVie, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. ""Medical stocks"" are shares of publicly traded companies that operate in the healthcare sector, including pharmaceutical and biotechnology firms, medical device makers, hospitals, diagnostic labs, and health services providers.",defenseworld.net,https://www.defenseworld.net/2025/11/04/best-medical-stocks-to-watch-today-november-2nd.html,https://images.financialmodelingprep.com/news/best-medical-stocks-to-watch-today-november-2nd-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 10:01:05,2025-11-04T10:01:05-05:00,2025-11-04,Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know,"Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2784395/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2784395,https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-is-attracting-investor-attention-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 10:16:06,2025-11-04T10:16:06-05:00,2025-11-04,International Markets and Lilly (LLY): A Deep Dive for Investors,Explore how Lilly's (LLY) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.,zacks.com,https://www.zacks.com/stock/news/2784463/international-markets-and-lilly-lly-a-deep-dive-for-investors?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_international_revenues-2784463,https://images.financialmodelingprep.com/news/international-markets-and-lilly-lly-a-deep-dive-for-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 10:44:17,2025-11-04T10:44:17-05:00,2025-11-04,"Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports","Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of products under Medicare, Endpoints New reported on Tuesday, citing sources familiar with the matter.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-novo-nordisk-near-white-house-deal-obesity-drug-prices-endpoints-new-2025-11-04/,https://images.financialmodelingprep.com/news/lilly-and-novo-nordisk-near-white-house-deal-on-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 10:46:05,2025-11-04T10:46:05-05:00,2025-11-04,Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term,"Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",zacks.com,https://www.zacks.com/stock/news/2784619/why-eli-lilly-lly-is-a-top-growth-stock-for-the-long-term?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_growth_score-2784619,https://images.financialmodelingprep.com/news/why-eli-lilly-lly-is-a-top-growth-stock-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 17:29:00,2025-11-04T17:29:00-05:00,2025-11-04,Obesity drugs may get Medicare access under deal with White House: reports,"The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medicare and Medicaid beneficiaries, according to media reports Tuesday.",marketwatch.com,https://www.marketwatch.com/story/obesity-drugs-may-get-medicare-access-under-deal-with-white-house-reports-e0472b38,https://images.financialmodelingprep.com/news/obesity-drugs-may-get-medicare-access-under-deal-with-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-04 20:10:00,2025-11-04T20:10:00-05:00,2025-11-04,Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.,"Stanley Druckenmiller has a fantastic investing track record, delivering a double-digit average annual return over time. The billionaire sold artificial intelligence (AI) leaders Nvidia and Palantir -- stocks that have advanced more than 1,000% over the past few years.",fool.com,https://www.fool.com/investing/2025/11/04/billionaire-stanley-druckenmiller-dropped-nvidia-a/,https://images.financialmodelingprep.com/news/billionaire-stanley-druckenmiller-dropped-nvidia-and-palantir-stock-and-20251104.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-05 05:00:00,2025-11-05T05:00:00-05:00,2025-11-05,XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development,"SHANGHAI , Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company (""Lilly"") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases. Through this collaboration, Lilly will gain access to Ailux's AI-powered bispecific antibody engineering platform, which integrates advanced structural modeling, generative design, and developability analytics to deliver therapeutic constructs with novel function, optimal efficacy and drug-like properties.",prnewswire.com,https://www.prnewswire.com/news-releases/xtalpi-subsidiary-ailux-announces-strategic-collaboration-with-lilly-to-advance-bispecific-antibody-development-302605279.html,https://images.financialmodelingprep.com/news/xtalpi-subsidiary-ailux-announces-strategic-collaboration-with-lilly-to-20251105.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-05 06:30:00,2025-11-05T06:30:00-05:00,2025-11-05,"This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?",Tirzepatide is used to treat both diabetes and obesity. Eli Lilly just struck a major deal with the world's largest retailer.,fool.com,https://www.fool.com/investing/2025/11/05/this-company-now-has-the-worlds-1-drug-should-you/,https://images.financialmodelingprep.com/news/this-company-now-has-the-worlds-no-1-drug-should-20251105.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-05 07:13:08,2025-11-05T07:13:08-05:00,2025-11-05,"White House speaking with Novo Nordisk, Eli Lilly about selling some obesity drugs for $149/mo: WSJ",CNBC's Andrew Ross Sorkin reports on the latest news.,youtube.com,https://www.youtube.com/watch?v=fzlwUHKi9-o,https://images.financialmodelingprep.com/news/white-house-speaking-with-novo-nordisk-eli-lilly-about-20251105.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-05 10:51:11,2025-11-05T10:51:11-05:00,2025-11-05,Here's Why Eli Lilly (LLY) is a Strong Momentum Stock,"Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",zacks.com,https://www.zacks.com/stock/news/2785762/here-s-why-eli-lilly-lly-is-a-strong-momentum-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_momentum_score-2785762,https://images.financialmodelingprep.com/news/heres-why-eli-lilly-lly-is-a-strong-momentum-20251105.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-05 13:16:21,2025-11-05T13:16:21-05:00,2025-11-05,"Trump, Eli Lilly to announce weight loss drug price cut on Thursday, CBS reports","U.S. President Donald Trump on Thursday is expected to announce a deal with officials from Eli Lilly and Novo Nordisk cutting the price of weight loss drugs in some cases to $150 a month, CBS reported on Wednesday, citing sources.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/trump-eli-lilly-announce-weight-loss-drug-price-cut-thursday-cbs-reports-2025-11-05/,https://images.financialmodelingprep.com/news/trump-eli-lilly-to-announce-weight-loss-drug-price-20251105.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 06:40:39,2025-11-06T06:40:39-05:00,2025-11-06,"Novo, Lilly shares rise as Trump obesity drug deal nears",Shares of obesity drugmakers Eli Lilly and Novo Nordisk rose early on Thursday in anticipation of a White House deal that would reduce prices of their blockbuster weight-loss treatments in return for expanded market access.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/,https://images.financialmodelingprep.com/news/novo-lilly-shares-rise-as-trump-obesity-drug-deal-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 06:45:00,2025-11-06T06:45:00-05:00,2025-11-06,"Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight","Based on these trial results, Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using the efficacy estimand.1 Results from the trial were presented at ObesityWeek 2025 and simultaneously published in The Lancet.",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-selective-amylin-agonist-eloralintide-demonstrated-meaningful-weight-loss-and-favorable-tolerability-in-a-phase-2-study-of-adults-with-obesity-or-overweight-302607061.html,https://images.financialmodelingprep.com/news/lillys-selective-amylin-agonist-eloralintide-demonstrated-meaningful-weight-loss-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 06:45:01,2025-11-06T06:45:01-05:00,2025-11-06,Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study,"Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, called eloralintide, helped patients with obesity or who are overweight lose 20.1% of their body weight on average at 48 weeks.",cnbc.com,https://www.cnbc.com/2025/11/06/eli-lilly-amylin-obesity-drug-study-weight-loss-trials.html,https://images.financialmodelingprep.com/news/eli-lilly-to-start-latestage-trials-on-amylin-obesity-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 06:49:13,2025-11-06T06:49:13-05:00,2025-11-06,Lilly's experimental drug shows promise with 20.1% weight loss in mid-stage trial,Eli Lilly said on Thursday its experimental obesity drug helped patients lose as much as 20.1% of their weight in a mid-stage trial.,reuters.com,https://www.reuters.com/sustainability/boards-policy-regulation/lillys-experimental-drug-shows-promise-with-201-weight-loss-mid-stage-trial-2025-11-06/,https://images.financialmodelingprep.com/news/lillys-experimental-drug-shows-promise-with-201-weight-loss-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 12:49:03,2025-11-06T12:49:03-05:00,2025-11-06,"President Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices","President Donald Trump announced deals with Eli Lilly and Novo Nordisk to slash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatments.",youtube.com,https://www.youtube.com/watch?v=Ku3Yb77pjZE,https://images.financialmodelingprep.com/news/president-trump-announces-deals-with-eli-lilly-novo-nordisk-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 13:02:59,2025-11-06T13:02:59-05:00,2025-11-06,"Lilly, Novo Will Lower Obesity Drug Prices in Trump Deal",Eli Lilly & Co. and Novo Nordisk A/S cut a deal with the Trump administration to lower prices on their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. President Donald Trump spoke about it in the Oval Office.,youtube.com,https://www.youtube.com/watch?v=vYRDaIMX2Gc,https://images.financialmodelingprep.com/news/lilly-novo-will-lower-obesity-drug-prices-in-trump-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 13:54:00,2025-11-06T13:54:00-05:00,2025-11-06,Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans,"Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month  INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-and-us-government-agree-to-expand-access-to-obesity-medicines-to-millions-of-americans-302607652.html,https://images.financialmodelingprep.com/news/lilly-and-us-government-agree-to-expand-access-to-obesity-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 14:42:36,2025-11-06T14:42:36-05:00,2025-11-06,"Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk","President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk to slash the prices of their blockbuster weight loss drugs.  Under the agreements, the monthly out-of-pocket cost of popular injections and upcoming pills could range from $50 to $350, depending on the dosage and insurance coverage a patient has.",cnbc.com,https://www.cnbc.com/2025/11/06/obesity-drug-prices-trump-deals-eli-lilly-novo-nordisk.html,https://images.financialmodelingprep.com/news/heres-how-much-weight-loss-drugs-could-cost-you-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 16:05:00,2025-11-06T16:05:00-05:00,2025-11-06,Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth,"INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-announces-two-new-executive-committee-members-and-expansion-of-leadership-roles-to-prepare-for-next-wave-of-growth-302606052.html,https://images.financialmodelingprep.com/news/lilly-announces-two-new-executive-committee-members-and-expansion-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-06 16:48:55,2025-11-06T16:48:55-05:00,2025-11-06,Eli Lilly expects US FDA approval for oral obesity drug in March 2026,"Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-expects-us-fda-approval-oral-obesity-drug-march-2026-2025-11-06/,https://images.financialmodelingprep.com/news/eli-lilly-expects-us-fda-approval-for-oral-obesity-20251106.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-07 00:51:57,2025-11-07T00:51:57-05:00,2025-11-07,Lilly's obesity drug Mounjaro becomes India's top-selling drug by value in October,"Eli Lilly's blockbuster obesity drug Mounjaro became India's top-selling drug by value for the month of October with sales hitting 1 billion rupees ($11.38 million), research firm Pharmarack said on Friday.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-obesity-drug-mounjaro-becomes-indias-top-selling-drug-by-value-october-2025-11-07/,https://images.financialmodelingprep.com/news/lillys-obesity-drug-mounjaro-becomes-indias-topselling-drug-by-value-20251107.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-07 12:33:23,2025-11-07T12:33:23-05:00,2025-11-07,"Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment","On Thursday, Eli Lilly and Co. (NYSE:LLY) released data from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 obese adults with at least one obesity-related health issue and without type 2 diabetes.",benzinga.com,https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48727525/eli-lillys-investigational-obesity-drug-shows-up-to-20-weight-loss-in-phase-2-study-analyst-sees-it-as-emerging-cornerstone-in-obesity-treatment,https://images.financialmodelingprep.com/news/eli-lillys-investigational-obesity-drug-shows-up-to-20-weight-20251107.jpeg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-08 03:45:00,2025-11-08T03:45:00-05:00,2025-11-08,Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.,"Eli Lilly struck a deal with President Donald Trump, lowering the prices of its blockbuster weight loss drugs. In return, Lilly gains exemption from import tariffs and other benefits.",fool.com,https://www.fool.com/investing/2025/11/08/eli-lilly-strikes-a-landmark-pricing-deal-with-the/,https://images.financialmodelingprep.com/news/eli-lilly-strikes-a-landmark-pricing-deal-with-the-us-20251108.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-08 05:10:00,2025-11-08T05:10:00-05:00,2025-11-08,Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030,"Eli Lilly has plenty of medium-term catalysts that should power a strong performance through 2030. Berkshire Hathaway, by contrast, is facing some headwinds that may limit its upside.",fool.com,https://www.fool.com/investing/2025/11/08/prediction-eli-lilly-will-be-worth-more-than-berks/,https://images.financialmodelingprep.com/news/prediction-eli-lilly-will-be-worth-more-than-berkshire-20251108.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-08 10:30:00,2025-11-08T10:30:00-05:00,2025-11-08,This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy,"Eli Lilly delivered fantastic third-quarter results, largely thanks to tirzepatide. The company's current lineup and pipeline make the stock attractive.",fool.com,https://www.fool.com/investing/2025/11/08/this-unstoppable-growth-stock-just-gave-investors/,https://images.financialmodelingprep.com/news/this-unstoppable-growth-stock-just-gave-investors-more-reasons-20251108.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-08 11:50:45,2025-11-08T11:50:45-05:00,2025-11-08,Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points,The watchlist stocks have bucked the market's recent volatility.,investors.com,https://www.investors.com/news/eli-lilly-ai-plays-5-stocks-near-buy-points/,https://images.financialmodelingprep.com/news/eli-lilly-and-these-ai-plays-lead-5-stocks-near-20251108.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-09 05:31:00,2025-11-09T05:31:00-05:00,2025-11-09,Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump,Eli Lilly (LLY 1.39%) and Novo Nordisk (NVO 1.89%) agreed to lower prices for their weight loss treatments in exchange for lower tariffs and expanded access.,fool.com,https://www.fool.com/investing/2025/11/09/huge-news-for-eli-lilly-stock-and-novo-nordisk-sto/,https://images.financialmodelingprep.com/news/huge-news-for-eli-lilly-stock-and-novo-nordisk-20251109.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-10 08:11:02,2025-11-10T08:11:02-05:00,2025-11-10,"Here Are Monday's Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More","The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close.",247wallst.com,https://247wallst.com/investing/2025/11/10/here-are-mondays-top-wall-street-analyst-research-calls-advanced-micro-devices-alphabet-apple-eli-lilly-carmax-hubspot-and-more/,https://images.financialmodelingprep.com/news/here-are-mondays-top-wall-street-analyst-research-calls-20251110.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-10 09:10:45,2025-11-10T09:10:45-05:00,2025-11-10,Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease,"MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth.",reuters.com,https://www.reuters.com/legal/transactional/eli-lilly-signs-deal-meiragtxs-gene-therapy-severe-eye-disease-2025-11-10/,https://images.financialmodelingprep.com/news/eli-lilly-signs-deal-for-meiragtxs-gene-therapy-for-severe-20251110.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-10 12:45:38,2025-11-10T12:45:38-05:00,2025-11-10,"Wall Street is Pounding the Table Over NVDA, RUN, LLY","In addition, according to analysts at UBS, it sees Nvidia guiding fourth quarter revenue to a range of $63 billion to $64 billion.",247wallst.com,https://247wallst.com/investing/2025/11/10/wall-street-is-pounding-the-table-over-nvda-run-lly/,https://images.financialmodelingprep.com/news/wall-street-is-pounding-the-table-over-nvda-run-20251110.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-11 10:50:08,2025-11-11T10:50:08-05:00,2025-11-11,Three Healthcare Buys That Wall Street Loves,New technologies and an aging population are lifting the healthcare sector. Immunotherapy and anti-obesity drugs are leading the way.,fool.com,https://www.fool.com/investing/2025/11/11/three-healthcare-buys-that-wall-street-loves/,https://images.financialmodelingprep.com/news/three-healthcare-buys-that-wall-street-loves-20251111.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-11 11:10:20,2025-11-11T11:10:20-05:00,2025-11-11,"Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?","Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.",zacks.com,https://www.zacks.com/stock/news/2789366/lilly-up-18-in-a-month-should-you-buy-sell-or-hold-the-stock?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2789366,https://images.financialmodelingprep.com/news/lilly-up-18-in-a-month-should-you-buy-20251111.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-11 15:20:00,2025-11-11T15:20:00-05:00,2025-11-11,Why cutting drug prices is pushing Eli Lilly's stock toward an all-time high,"Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing a trillion-dollar valuation.",marketwatch.com,https://www.marketwatch.com/story/why-cutting-drug-prices-is-pushing-eli-lillys-stock-toward-an-all-time-high-edc0c453,https://images.financialmodelingprep.com/news/why-cutting-drug-prices-is-pushing-eli-lillys-stock-toward-20251111.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-11 21:34:47,2025-11-11T21:34:47-05:00,2025-11-11,"Eli Lilly drops CVS drug plan for workers after Novo obesity deal, Bloomberg News reports","Eli Lilly is dropping CVS Health's drug benefit plan for its employees after CVS stopped covering its weight-loss drug in favor of a rival medication from Novo Nordisk , Bloomberg News reported on Tuesday, citing people familiar with the matter.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-drops-cvs-drug-plan-workers-after-novo-obesity-deal-bloomberg-news-2025-11-12/,https://images.financialmodelingprep.com/news/eli-lilly-drops-cvs-drug-plan-for-workers-after-20251111.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 04:12:49,2025-11-12T04:12:49-05:00,2025-11-12,Eli Lilly and Company $LLY Stake Boosted by Accredited Investors Inc.,"Accredited Investors Inc. increased its position in shares of Eli Lilly and Company (NYSE: LLY) by 17.1% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,851 shares of the company's stock after acquiring an additional 561",defenseworld.net,https://www.defenseworld.net/2025/11/12/eli-lilly-and-company-lly-stake-boosted-by-accredited-investors-inc.html,https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-stake-boosted-by-accredited-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 04:22:00,2025-11-12T04:22:00-05:00,2025-11-12,This Unstoppable Growth Stock Just Delivered More Good News: Time to Buy?,"Eli Lilly released more positive mid-stage clinical trial results for a weight management candidate. The company should dominate this area through the end of the decade, at least, despite the competition.",fool.com,https://www.fool.com/investing/2025/11/12/this-unstoppable-growth-stock-just-delivered-more/,https://images.financialmodelingprep.com/news/this-unstoppable-growth-stock-just-delivered-more-good-news-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 07:01:00,2025-11-12T07:01:00-05:00,2025-11-12,PRIMECAP Management's Strategic Moves: Hess Corp Exit and Chevron Corp Addition,"Analyzing the Third Quarter 2025 13F Filing PRIMECAP Management (Trades, Portfolio) recently submitted its 13F filing for the third quarter of 2025, offering a",gurufocus.com,https://www.gurufocus.com/news/3203110/primecap-managements-strategic-moves-hess-corp-exit-and-chevron-corp-addition,https://images.financialmodelingprep.com/news/primecap-managements-strategic-moves-hess-corp-exit-and-chevron-corp-20251112.png
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 08:20:04,2025-11-12T08:20:04-05:00,2025-11-12,Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Nov 2025),"From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather this year.",247wallst.com,https://247wallst.com/forecasts/2025/11/12/eli-lilly-lly-stock-price-prediction-and-forecast-2025-2030/,https://images.financialmodelingprep.com/news/eli-lilly-nyse-lly-stock-price-prediction-and-forecast-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 09:45:00,2025-11-12T09:45:00-05:00,2025-11-12,Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock,"Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed.",fool.com,https://www.fool.com/investing/2025/11/12/forget-recursion-pharmaceuticals-this-could-be-an/,https://images.financialmodelingprep.com/news/forget-recursion-pharmaceuticals-this-could-be-an-even-better-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 09:54:40,2025-11-12T09:54:40-05:00,2025-11-12,Cramer's Mad Dash: Eli Lilly,Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly.,youtube.com,https://www.youtube.com/watch?v=FTOYFD8WcYc,https://images.financialmodelingprep.com/news/cramers-mad-dash-eli-lilly-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 10:01:52,2025-11-12T10:01:52-05:00,2025-11-12,"IBM's Quantum Push Intensifies, LLY Price Target Hike, ONON Soars 20% on Earnings",ON Holding (ONON) jumped higher with an earnings beat and guidance raise giving shares a platform to rally. Diane King Hall points to sales doubling in the Asia-Pacific region as a big catalyst.,youtube.com,https://www.youtube.com/watch?v=t00FQnRTHWM,https://images.financialmodelingprep.com/news/ibms-quantum-push-intensifies-lly-price-target-hike-onon-soars-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 10:20:08,2025-11-12T10:20:08-05:00,2025-11-12,Is Eli Lilly Stock's Run Too Hot? Here Is How It Can Crash,"Eli Lilly stock (NYSE: LLY) has surged by 21% this month, driven by strong third-quarter earnings and a favorable obesity drug pricing deal with the U.S. government. However, this recent success doesn't mean the company is invulnerable to challenges.",forbes.com,https://www.forbes.com/sites/greatspeculations/2025/11/12/is-eli-lilly-stocks-run-too-hot-here-is-how-it-can-crash/,https://images.financialmodelingprep.com/news/is-eli-lilly-stocks-run-too-hot-here-is-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 11:42:44,2025-11-12T11:42:44-05:00,2025-11-12,"Eli Lilly Stock: This Trade On The Rising Stock Holds $1,415 In Profit Potential",Eli Lilly's strong price action and high ratings present a bull call spread trading opportunity with large profit potential and clearly defined risk parameters.,investors.com,https://www.investors.com/research/options/eli-lilly-stock-lly-options-bull-call-spread-pharma-drugs-investing-markets/,https://images.financialmodelingprep.com/news/eli-lilly-stock-this-trade-on-the-rising-stock-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-12 15:30:30,2025-11-12T15:30:30-05:00,2025-11-12,MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential,"MeiraGTx Holdings plc secures a transformative partnership with Eli Lilly, granting worldwide rights to its AAV-AIPL1 gene therapy for LCA4. MGTX receives $75 million upfront, up to $400 million in milestones, and tiered royalties, strengthening its financial position and reducing near-term dilution risk. The company's riboswitch technology and multiple collaborations, including with Johnson & Johnson and Hologen, highlight its innovation and diversified pipeline.",seekingalpha.com,https://seekingalpha.com/article/4842666-meiragtx-latest-eli-lilly-partnership-ignites-riboswitch-technology-potential,https://images.financialmodelingprep.com/news/meiragtx-latest-eli-lilly-partnership-ignites-riboswitch-technology-potential-20251112.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-13 01:17:00,2025-11-13T01:17:00-05:00,2025-11-13,"Bitget Lists LLY, MA, UNH Stock Index Perpetual Futures as Cumulative Trading Volume on Bitget hits $3 Billion","VICTORIA, Seychelles, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), has announced the official addition of LLYUSDT, MAUSDT, UNHUSDT stock index perpetual futures, expanding its range of Real World Asset (RWA) products for global traders. Bitget users can access these contracts with leverage of up to 10x.",globenewswire.com,https://www.globenewswire.com/news-release/2025/11/13/3187009/0/en/Bitget-Lists-LLY-MA-UNH-Stock-Index-Perpetual-Futures-as-Cumulative-Trading-Volume-on-Bitget-hits-3-Billion.html,https://images.financialmodelingprep.com/news/bitget-lists-lly-ma-unh-stock-index-perpetual-futures-20251113.png
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-13 04:25:00,2025-11-13T04:25:00-05:00,2025-11-13,1 Incredible Reason to Buy LLY's Stock in November,Eli Lilly is the market-share leader for weight-loss drugs. Coverage by government insurance programs is a huge win for the company.,fool.com,https://www.fool.com/investing/2025/11/13/incredible-reason-buy-lilly-stock-november-lly/,https://images.financialmodelingprep.com/news/1-incredible-reason-to-buy-llys-stock-in-november-20251113.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-13 07:15:41,2025-11-13T07:15:41-05:00,2025-11-13,"Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs",Telehealth company Mangoceuticals said on Thursday it has partnered with Eli Lilly and Novo Nordisk to sell the drugmakers' blockbuster weight-loss drugs through its platform.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/mangoceuticals-partners-with-lilly-novo-nordisk-sell-weight-loss-drugs-2025-11-13/,https://images.financialmodelingprep.com/news/mangoceuticals-partners-with-lilly-novo-nordisk-to-sell-weightloss-20251113.jpg
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-13 11:03:00,2025-11-13T11:03:00-05:00,2025-11-13,Jefferies Group's Strategic Move: Vanguard Information Technology ETF Takes Center Stage,"Jefferies Group (Trades, Portfolio)'s Latest 13F Filing Reveals Strategic Portfolio Adjustments Jefferies Group (Trades, Portfolio) recently submitted its 13F",gurufocus.com,https://www.gurufocus.com/news/3207102/jefferies-groups-strategic-move-vanguard-information-technology-etf-takes-center-stage,https://images.financialmodelingprep.com/news/jefferies-groups-strategic-move-vanguard-information-technology-etf-takes-center-20251113.png
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-13 13:51:07,2025-11-13T13:51:07-05:00,2025-11-13,Can Equities Stabilize after the Government Reopens?,"As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.",zacks.com,https://www.zacks.com/commentary/2790817/can-equities-stabilize-after-the-government-reopens?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2790817,https://images.financialmodelingprep.com/news/can-equities-stabilize-after-the-government-reopens-20251113.webp
LLY,2025-10-30,2025-10-23,2025-11-13,LLY,,2025-11-13 14:04:16,2025-11-13T14:04:16-05:00,2025-11-13,"Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs","Novo Nordisk and Eli Lilly do not have a weight-loss drug partnership with telehealth website Mangoceuticals Inc , spokespeople for both companies said, rejecting a press release issued by the company on Thursday that described arrangements with the two leading drugmakers.",reuters.com,https://www.reuters.com/legal/litigation/novo-nordisk-lilly-deny-partnership-with-mangoceuticals-obesity-drugs-2025-11-13/,https://images.financialmodelingprep.com/news/novo-nordisk-lilly-deny-partnership-with-mangoceuticals-on-obesity-20251113.jpg
